Production (Stage)
BioAtla, Inc.
BCAB
$0.3896
$0.00832.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | 6.05% | -28.94% | |||
| Gross Profit | -6.05% | -115.94% | |||
| SG&A Expenses | 14.48% | -21.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.43% | -27.06% | |||
| Operating Income | -8.43% | -44.13% | |||
| Income Before Tax | -3.02% | -40.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.02% | -40.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.02% | -40.60% | |||
| EBIT | -8.43% | -44.13% | |||
| EBITDA | -8.83% | -45.05% | |||
| EPS Basic | 12.21% | -36.89% | |||
| Normalized Basic EPS | 12.17% | -36.82% | |||
| EPS Diluted | 12.21% | -36.89% | |||
| Normalized Diluted EPS | 12.17% | -36.82% | |||
| Average Basic Shares Outstanding | 17.31% | 2.73% | |||
| Average Diluted Shares Outstanding | 17.31% | 2.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||